ResearchForecast

  A recently published study by FMI expects the global Fuchs Endothelial Corneal Dystrophy (FECD) market to augment at a 7.5% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 370 Billion is expected for the market. The primary variables impacting the market growth rate include an increase in the prevalence of Fuchs' endothelial corneal dystrophy, an increase in the number of senior persons, and growing healthcare spending. Get Full Access @ https://www.futuremarketinsights.com/reports/fuchs-endothelial-corneal-dystrophy-fecd-market Furthermore, advances in medical technology, increased demand for corneal transplantation, and rising attempts by governmental and private organizations to raise awareness about eye disorders and corneal donation are factors that will propel the Fuchs' endothelial corneal dystrophy market forward. An increase in research on cellular treatment techniques and rising demand for eye care would benefit the Fuchs...